HIKAL ANNOUNCES MANUFACTURING AGREEMENT WITH PFIZER FOR SUPPLY OF API’s

HIKAL ANNOUNCES MANUFACTURING AGREEMENT WITH PFIZER FOR SUPPLY OF API’s

Mumbai, India. (January 7, 2008) – Hikal Ltd. today announced that it has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (API’s) with Pfizer Inc., a global leader in Pharmaceuticals.

“We are extremely pleased to be selected as a long term contract manufacturer by Pfizer”, said Jai Hiremath, Vice Chairman & Managing Director of Hikal Ltd. “This agreement will have a substantial impact on our Pharmaceutical business in the coming years”. 

"We look forward to working with Hikal, a respected contract manufacturing company and are delighted that they are able to contribute towards supply of APIs for Pfizer products", said Mr. Peter Stevenson, Vice-President, Global Contract Manufacturing, Procurement and Pfizer Center Source, Pfizer Inc. 

Terms of the agreement were not disclosed.

About Hikal:

Hikal is a reliable long-term outsourcing partner to companies in the Pharmaceuticals, Agrochemicals and Specialty Chemicals industry. The company has been supplying key APIs and intermediates, manufactured using stringent global quality standards, for it’s customers  in the United States, Europe and Japan. Hikal’s advanced manufacturing facilities have been inspected and approved by globally recognized bodies such as the USFDA. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat) respectively. The crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art research centers and pilot plant facilities located at Bangalore and Taloja respectively.

About Pfizer:

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals. Every day, approximately 90,000 colleagues in more than 150 countries work to discover, develop, manufacture and deliver quality, safe and effective prescription medicines to patients.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.